Drug Profile
CZ 2294
Alternative Names: Cz2294Latest Information Update: 01 Oct 2021
Price :
$50
*
At a glance
- Originator Captozyme
- Developer Arranta Bio
- Class Enzymes
- Mechanism of Action Oxalate inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Hyperoxaluria
Most Recent Events
- 14 Aug 2016 Investigation in Hyperoxaluria in USA (unspecified route)